Hamilton Thorne Ltd. (HTLZF)
| Previous close | 1.0300 |
| Open | 1.0300 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's range | 1.0300 - 1.0300 |
| 52-week range | 0.8030 - 1.2500 |
| Volume | |
| Avg. volume | 6,518 |
| Market cap | 157.341M |
| Beta (5Y monthly) | 0.29 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
Hamilton Thorne Reports Record Revenue and EBITDA for the Quarter and Year Ended December 31, 2023
Revenue of $67.2 million for the year and $18.4 million for the 4th quarter; Adj. EBITDA of $11.5 million for the year and $3.7 million for the quarterBEVERLY, Mass. and TORONTO, March 27, 2024 (GLOBE NEWSWIRE) -- Hamilton Thorne Ltd. (TSX: HTL), a leading provider of precision instruments, laboratory equipment, consumables, software and services to the Assisted Reproductive Technologies (ART), research, and cell biology markets, today reported audited financial results for the fourth quarter an
- GlobeNewswire
Hamilton Thorne to Announce Q4 and Full Year 2023 Financial Results and Hold Conference Call on March 27, 2024
BEVERLY, Mass. and TORONTO, March 21, 2024 (GLOBE NEWSWIRE) -- Hamilton Thorne Ltd. (TSX: HTL), a leading provider of precision instruments, laboratory equipment, consumables, software and services to the Assisted Reproductive Technologies (ART), research, and cell biology markets, today announced that it will release its financial results for the three and twelve months ended December 31, 2023 before market open on Wednesday, March 27, 2024. The press release, with accompanying financial inform
- GlobeNewswire
Hamilton Thorne Appoints Dr. Ekaterina (Kate) Torchilin as President and CEO
David Wolf to move to Executive ChairmanBEVERLY, Mass. and TORONTO, Dec. 21, 2023 (GLOBE NEWSWIRE) -- Hamilton Thorne Ltd. (TSX: HTL), a leading provider of precision instruments, consumables, software and services to the Assisted Reproductive Technologies (ART), research, and cell biology markets, today announced the appointment, of Dr. Ekaterina (Kate) Torchilin as its new President and Chief Executive Officer, effective January 15, 2024. Dr. Torchilin is succeeding David Wolf, who is retiring
